News
Latest News
- 24 March 2023 – Landmark XF-73 Phase 2 data published in US journal
- 16 March 2023 – Result of General Meeting and Total Voting Rights
- 15 March 2023 – Result of Open Offer
- 28 February 2023 – Form of Proxy
- 28 February 2023 – Open Offer Application Form
- 28 February 2023 – Circular to Shareholders
- 27 February 2023 – Neil Clark speaks to Endpoint – ‘UK biotech hands off mid-stage C. difficile drug in up to $570M deal’
- 24 February 2023 – Issue of Equity
- 24 February 2023 – Agreement with Sebela Pharmaceuticals for NTCD-M3
- 25 January 2023 – US Center for Disease Control review paper
- 19 January 2023 – US Review on prevention of surgical site infection endorsing value of nasal decolonisation
- 22 December 2022 -Year End Trading Update
- 7 December 2022 – FDA/CDC highlight need for infection preventions
- 7 December 2022 – XF-73 Nasal Phase 3 development plans finalised
- 21 November 2022 – Destiny Pharma’s AMR Paper
- 18 November 2022 – Dr Bill Love speaks to Proactive Investors about how Destiny Pharma is addressing the Global threat of superbugs and AMR
- 15 November 2022 – XF-73 Dermal infection project advances into clinically enabling safety study with US Government’s NIAID
- 14 November 2022 – New report highlights fast growing market for Live Biotherapeutics, Destiny Pharma’s NTCD-M3 is leading play in this sector
- 19 October 2022 – Destiny Pharma R&D Investor Update meeting presentation recording
- 08 September 2022 – Interim results for six months ended 30 June 2022
- 07 September 2022 – Destiny Pharma CEO, Neil Clark, to present at the HC Wainwright 24th Annual Global Investment Conference
- 07 September 2022 – Positive update from European Medicine Agency (EMA) on NTCD-M3 Phase 3 development plans
- 22 August 2022 – Notice of Interim Results and Investor Presentation
- 28 July 2022 – Chair’s Investor Update
- 26 July 2022 – Publication of new data on NTCD-M3
- 19 July 2022 – Positive update from US FDA on XF-73 Phase 3
- 12 July 2022 – Destiny Pharma receives award from the Cystic Fibrosis Foundation
- 07 July 2022 – Destiny Pharma announce publication of XF-73 drug synergy data
- 05 July 2022 – Destiny Pharma announces start of a new XF-73 research programme
- 27 May 2022 – Result of Annual General Meeting and Strategy Update
- 26 May 2022 – Destiny Pharma plc Board changes
- 12 May 2022 – Landmark NTCD-M3 data to be presented at Anaerobe
- 04 May 2022 – Destiny’s Chief Business Officer, Dr Stephanie Bewick, speaks to Labiotech about her role
- 03 May 2022 – Destiny Pharma appoints Dr Yuri Martina as Chief Medical Officer
- 27 April 2022 – Posting of Annual Report and Notice of AGM
- 12 April 2022 – Audited results for year ended 31 December 2021
- 31 March 2022 – Presenting data at the ECCMID 2022 Congress
- 28 March 2022 – Result of General Meeting and Total Voting Rights
- 25 March 2022 – Result of Open Offer
- 25 March 2022 – Destiny’s microbiome project article published in Vantage
- 23 March 2022 – Destiny Pharma publish in the European Biopharmaceutical Review Journal “Global Rise in AMR Threatens Infection Armageddon”
- 22 March 2022 – Exercise of Options and Total Voting Rights
- 17 March 2022 – Open Offer Application Form
- 17 March 2022 – Form of Proxy
- 17 March 2022 – Form of Proxy
- 09 March 2022 – Circular to shareholders
- 08 March 2022 – Fundraising
- 08 February 2022 – Positive feedback from EMA on XF-73 Nasal gel Phase 3 programme
- 01 February 2022 – Positive data in XF-73 Dermal study with NIAID
- 24 January 2022 – Clinical and commercial opportunity of NTCD-M3
- 21 January 2022 – Destiny Pharma Lancet Report
- 17 January 2022 – Strategy/Company/Ops Update